Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Notice of Preliminary Results

29th Mar 2022 07:00

RNS Number : 3109G

Arecor Therapeutics PLC

29 March 2022

Arecor Therapeutics plc

("Arecor" or the "Group")

NOTICE OF PRELIMINARY RESULTS

Cambridge, UK, 29 March 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, will announce its preliminary results for the year ended 31 December 2021 on Monday 25 April 2022.

Sarah Howell, Chief Executive Officer, and Susan Lowther, Chief Financial Officer, will host an in-person briefing for analysts at 11:00am BST on the day of the results at the offices of Panmure Gordon, One New Change, London, EC4M 9AF. There will also be a live webcast and conference call with a Q&A session.

For more details or to attend the briefing, please contact [email protected]

-ENDS-

For more information, please contact:

Arecor Therapeutics plc	www.arecor.com
Dr Sarah Howell, Chief Executive Officer	Tel: +44 (0) 1223 426060 Email: [email protected]

Susan Lowther, Chief Financial Officer	Tel: +44 (0) 1223 426060 Email: [email protected]

Mo Noonan, Communications	Tel: +44 (0) 7876 444977 Email: [email protected]

Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking)	Tel: +44 (0) 20 7886 2500

Consilium Strategic Communications
Chris Gardner, David Daley, Angela Gray	Tel: +44 (0) 20 3709 5700 Email: [email protected]

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOREAEDPAESAEAA

Related Shares:

FTSE 100 Latest

Value8,608.48

Change-26.32